Located within the beautiful Truckee Meadows in the Reno-Tahoe area, Strykagen is a biopharmaceutical company devoted to the development of transforming therapeutics and diagnostics for life-threatening rare muscle diseases. There is currently an unmet medical need for new therapies for the muscular dystrophies many of which have no cure and limited treatment options.

We are currently working on developing therapeutics for Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Merosin deficient congenital muscular dystrophy (MDC1A) and Limb Girdle Muscular Dystrophies (LGMD).

Strykagen has exclusive licenses for worldwide patent pending technologies that stabilize the myomatrix and prevent muscle disease progression. These include biologic and small molecule therapeutics that target disease modifiers which have been shown to prevent muscle disease progression. We are also developing non-invasive tests to assist in the diagnosis and prognosis of muscular dystrophy.